Deguchi H, Deguchi K, Tsukada T, Murashima S, Iwasaki E, Tsuda M, Kobayashi T, Shirakawa S
Second Department of Internal Medicine, Mie University School of Medicine, Tsu.
Intern Med. 1994 Feb;33(2):100-2. doi: 10.2169/internalmedicine.33.100.
Octreotide acetate, a long-acting somatostatin analogue, is effective in controlling and markedly reducing the symptoms of carcinoid crisis. We report a patient with carcinoid syndrome with prolonged survival for 4.5 years with high dose octreotide therapy and survived for 7.5 years after the first flushing, in spite of episodes of severe carcinoid crisis. Dose escalation was required in order to control carcinoid symptoms, and the final dosage was 5,950 micrograms/day. Although administration of such a high dosage of octreotide has never been reported before, we found that octreotide could be used at this dosage safely without inducing serious side effects, and probably prolonged the patient's survival. Our experience with this case indicates that octreotide acetate is an effective drug in controlling carcinoid crisis and prolonging survival without serious side effects.
醋酸奥曲肽是一种长效生长抑素类似物，对控制类癌危象症状并显著减轻症状有效。我们报告了1例类癌综合征患者，接受高剂量奥曲肽治疗后生存长达4.5年，首次出现潮红后存活了7.5年，尽管发生过严重的类癌危象。为控制类癌症状需要增加剂量，最终剂量为5950微克/天。虽然此前从未有过如此高剂量奥曲肽给药的报道，但我们发现以该剂量使用奥曲肽是安全的，未引起严重副作用，且可能延长了患者生存期。我们对该病例的经验表明，醋酸奥曲肽是控制类癌危象、延长生存期且无严重副作用的有效药物。
